|
Avodart |
| 30
Avodart 0.5mg |
|
Men
|
| 60
Avodart 0.5mg |
|
| 90
Avodart 0.5mg |
|
Avodart
Medication Drug Information
The following information is
intended to supplement, not substitute for, the expertise and
judgment of your physician, pharmacist or other healthcare
professional. It should not be construed to indicate that use of
the drug is safe, appropriate, or effective for you. Consult
your healthcare professional before using this drug.
Online Avodart Use Indication:
AVODART is
indicated for the treatment of symptomatic benign prostatic
hyperplasia (BPH)
in men with an enlarged prostate to:
• Improve symptoms
• Reduce the risk of acute urinary retention
• Reduce the risk of the need for BPH-related surgery
Medication Avodart Side Effects:
Patients
experience a full 12 hours of symptom relief with Avodart Nasal
Spray. However, as with any medication, Avodart Nasal Spray may
cause side effects in some patients. For adults and children 12
years and older with seasonal allergic rhinitis or nonallergic
vasomotor rhinitis, bitter taste, headache, somnolence, nasal
burning and rhinitis are the most commonly reported adverse
events. However, in large patient studies, the
discontinuation rates (2.2%) due to adverse events while taking
Avodart Nasal Spray were not significantly different than those
for placebo (2.8%). Other adverse events that occurred in
seasonal allergic rhinitis patients 5 to 11 years of age treated
with Avodart Nasal Spray and that were not similarly represented
in the adult population include rhinitis/cold symptoms, cough,
and conjunctivitis.
Precautions on using Avodart
AVODART is
contraindicated for use in women and children. AVODART is
contraindicated for patients with known hypersensitivity to
dutasteride, other 5α-reductase inhibitors, or any component of
the preparation. Lower urinary tract symptoms of BPH can be
indicative of other urological diseases, including prostate
cancer. Patients should be assessed to rule out other urological
diseases prior to treatment with AVODART. Patients with a large
residual urinary volume and/or severely diminished urinary flow
may not be good candidates for 5α-reductase inhibitor therapy
and should be carefully monitored for obstructive uropathy.
Medication Avodart Drug Interaction:
Care
should be taken when administering dutasteride to patients
taking potent, chronic CYP3A4 inhibitors (see PRECAUTIONS: Use
with Potent CYP3A4 Inhibitors). Dutasteride does not inhibit the
in vitro metabolism of model substrates for the major human
cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and
CYP3A4) at a concentration of 1,000 ng/mL, 25 times greater than
steady-state serum concentrations in humans. In vitro studies
demonstrate that dutasteride does not displace warfarin,
diazepam, or phenytoin from plasma protein binding sites, nor do
these model compounds displace dutasteride.
Medication
Avodart Overdose:
In
volunteer studies, single doses of dutasteride up to 40 mg (80
times the therapeutic dose)
for 7 days have been administered without significant safety
concerns. In a clinical study, daily
doses of 5 mg (10 times the therapeutic dose) were administered
to 60 subjects for 6 months with no additional adverse effects
to those seen at therapeutic doses of 0.5 mg. There is no
specific antidote for dutasteride. Therefore, in cases of
suspected overdosage symptomatic and supportive treatment should
be given as appropriate, taking the long half-life of
dutasteride into consideration.
|
